The Split Vote: UroGen and the FDA

What It Covers

UroGen Pharma CEO Liz Barrett recounts navigating a split 4-5 FDA advisory committee vote for bladder cancer drug Jelmido, where only two of nine panelists were urologists. She details the ten-day period after the negative vote, strategic FDA negotiations, and ultimate approval despite stock dropping 50 percent.

Key Questions Answered

• •FDA Advisory Panel Composition Risk: UroGen faced an oncology advisory committee with only two urologists among nine voters for a urothelial cancer drug. The remaining seven oncology specialists lacked expertise in low-grade bladder cancers, repeatedly confusing disease progression patterns. Companies should advocate for specialist representation matching their therapeutic area before ODAC meetings to avoid knowledge gaps affecting votes.
• •RTGel Delivery Technology: The reverse thermal gel remains liquid when chilled below body temperature, then solidifies at 98.6 degrees Fahrenheit inside the bladder. This polymer-based system releases mitomycin C chemotherapy locally over several hours, eliminating systemic side effects while patients walk out immediately after fifteen-minute treatments. The six-week once-weekly protocol requires no recovery time versus surgical tumor removal.
• •Post-Rejection FDA Strategy: After the split vote, Barrett immediately contacted regulators within hours rather than accepting defeat. The company secured an in-person meeting within ten days, where they challenged the FDA's contradictory messaging about randomized trials versus single-arm study approvals. This direct engagement resulted in a draft approval label the same day, demonstrating persistence can reverse negative advisory outcomes.
• •Commercial Complexity in Specialty Procedures: Self-commercializing a procedure-based drug requires addressing operational burdens physicians face with mixing, chilling, and administering treatments versus simple pills or infusions. UroGen underestimated these logistical challenges with their first drug Jelmido, learning that seamless practice integration matters more than clinical efficacy data when changing physician behavior from surgical standards of care.
• •Leadership Through Regulatory Uncertainty: Barrett maintained investor confidence during a mandatory quiet period between FDA meeting and approval by acknowledging a path forward without revealing confidential negotiations. She simultaneously prepared commercial teams for launch without confirmation, balancing legal disclosure limits with organizational momentum. This approach prevented panic selling while preserving regulatory compliance during the ten-day blackout window.